Journal: Oncology Reports

Article Title: Platelets and MMP?9 contribute to esophageal cancer invasion via CD40?CD154 interactions

doi: 10.3892/or.2025.8912

Figure Lengend Snippet: Changes in MMP-9 expression caused by the CD40-CD154 interaction in TE cells. (A) Qualitative analysis of MMP-9 secretion from TE cells using gelatin zymography. Increased MMP-9 secretion was observed in high CD40 expression cells (TE-5 and −10), regardless of the baseline MMP-9 secretion level without CD154 stimulation. (B) Quantitative analysis of MMP-9 secretion from TE cells using an ELISA. Increased MMP-9 secretion was observed in TE-5 and −10 cells. (C) Quantitative analysis of MMP-9 mRNA expression in TE cells via reverse transcription-quantitative PCR. MMP-9 mRNA expression upregulation was observed in high CD40 expression cells (TE-5 and −10). The Mann-Whitney U test was performed using GraphPad Prism 9 software. n.d., not detected; rsCD154, recombinant soluble CD154.

Article Snippet: The concentrations of soluble CD154 (sCD154) and MMP-9 in the culture supernatant were measured using ELISA kits (Quantikine ® ELISA: Human CD40 Ligand/TNFSF5 Immunoassay; cat. no. DCDL40; R&D Systems, Inc.; Quantikine ® ELISA: Human MMP-9; cat. no. DMP900; R&D Systems, Inc.) according to the respective manufacturer's instructions.

Techniques: Expressing, Zymography, Enzyme-linked Immunosorbent Assay, Reverse Transcription, Real-time Polymerase Chain Reaction, MANN-WHITNEY, Software, Recombinant

Journal: International journal of molecular sciences

Article Title: Exosomal CD40, CD25, and Serum CA19-9 as Combinatory Novel Liquid Biopsy Biomarker for the Diagnosis and Prognosis of Patients with Pancreatic Ductal Adenocarcinoma.

doi: 10.3390/ijms26041500

Figure Lengend Snippet: Figure 2. Validation of exosomal CD40 as a novel biomarker for pancreatic cancer and pancreatitis. (A) Normalized signal intensities of exosomal surface protein CD40 in plasma exosomes of controls (n = 51), patients with pancreatitis (n = 21), and patients with PDAC (n = 48) (Mann–Whitney test, *** p = 0.0010, **** p < 0.0001). (B,C) Correlations between normalized signal intensities of exosomal surface protein CD40 with nodal category and perineural invasion status in patients with PDAC. (D) Kaplan–Meier curves displaying survival analysis of patients with PDAC (Gehan–Breslow– Wilcoxon). Data are mean ± s.d.

Article Snippet: Serum CA19-9, CD40 and CD25 protein levels in analyzed groups were assessed using the Cancer Antigen CA19-9 Human ELISA Kit (Catalog No. ab108642, Abcam), Human CD40 Quantikine ELISA Kit (Catalog No. DCCD40 R&D systems, Minneapolis, MN, USA) and Human CD25/IL-2R alpha Quantikine ELISA Kit (Catalog No. DR2A00 R&D systems), according to the manufacturer’s protocol.

Techniques: Biomarker Discovery, Clinical Proteomics, MANN-WHITNEY

Journal: International journal of molecular sciences

Article Title: Exosomal CD40, CD25, and Serum CA19-9 as Combinatory Novel Liquid Biopsy Biomarker for the Diagnosis and Prognosis of Patients with Pancreatic Ductal Adenocarcinoma.

doi: 10.3390/ijms26041500

Figure Lengend Snippet: Figure 5. Receiver operating characteristic (ROC) curves analysis of exosome-surface markers and CA19-9. (A) ROC curves discriminating the PDAC group from clinical controls. Each ROC curve shows the single markers exo-CD40, exo-CD25, and CA19-9 and the combination with the highest AUC. (B) Table representing the cut-off values, sensitivity, specificity for exo-CD40, exo-CD25, and CA19-9 surface markers and the selected combination. (C) ROC curves discriminating the PDAC group from pancreatitis. (D) Table representing the cut-off values, sensitivity, specificity for exo-CD40, exo-CD25, and CA19-9 surface markers and the selected combination.

Article Snippet: Serum CA19-9, CD40 and CD25 protein levels in analyzed groups were assessed using the Cancer Antigen CA19-9 Human ELISA Kit (Catalog No. ab108642, Abcam), Human CD40 Quantikine ELISA Kit (Catalog No. DCCD40 R&D systems, Minneapolis, MN, USA) and Human CD25/IL-2R alpha Quantikine ELISA Kit (Catalog No. DR2A00 R&D systems), according to the manufacturer’s protocol.

Techniques: